$0.25
-5.8%Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Last Annual Value
146.67M
3-Year CAGR
45%
5-Year CAGR
25%
10-Year CAGR
12%
| Company | shares-outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Tevogen Bio Holdings Inc. NASDAQ:TVGN | 146.67M | -3.9% | 25.1% | N/A | |
![]() Whitehawk Therapeutics Inc NASDAQ:WHWK | 61.89M | 32.0% | 47.3% | N/A | |
![]() Cognition Therapeutics, Inc. NASDAQ:CGTX | 72.77M | 34.3% | 26.8% | N/A | |
![]() TuHURA Biosciences, Inc. NASDAQ:HURA | 47.93M | 299.3% | 343.8% | 205.0% | |
![]() Instil Bio, Inc. NASDAQ:TIL | 6.67M | 0.8% | 4.7% | N/A | |
![]() Surrozen, Inc. NASDAQ:SRZN | 7.48M | 54.7% | 26.2% | N/A | |
![]() Greenwich LifeSciences, Inc. NASDAQ:GLSI | 13.53M | 1.8% | 0.9% | N/A | |
![]() Atossa Therapeutics, Inc. NASDAQ:ATOS | 8.61M | 0.8% | 2.0% | 42.7% | |
![]() Alto Neuroscience, Inc. NYSE:ANRO | 28.85M | 2.4% | 2.4% | N/A | |
![]() C4 Therapeutics, Inc. NASDAQ:CCCC | 82.89M | 18.6% | 12.5% | N/A | |
![]() Nuvectis Pharma, Inc. NASDAQ:NVCT | 21.81M | 11.9% | 11.4% | N/A |
Continue your TVGN research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.